Furthermore, treatment with cisplatin-based regimens is a strong risk factor for DVT/VTE in patients with non-small cell lung cancer [25]; the vast majority of the patients included in this study were treated with cisplatin-based regimens, as these treatments are still the first choice in patients with advanced adenocarcinoma not bearing a EGFR- or ALK-mutation according to the current Swedish guidelines [11]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.